Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab Plus Etoposide/Platinum Versus Etoposide/Platinum in Subjects With Newly Diagnosed Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC)
Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab Plus Etoposide/Platinum Versus Etoposide/Platinum in Subjects With Newly Diagnosed Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC)
The purpose of the study is to determine whether the addition of Ipilimumab to Etoposide and Platinum therapy will extend the lives of patients with Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) more than Etoposide and Platinum therapy alone.
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.
Inclusion Criteria:
Exclusion Criteria:
Indianapolis, Indiana 46237, United States
Cherry Hill, New Jersey 08003, United States
Provincia de Sante Fe, S2000DSV, Argentina
Sao Paulo/SP, CEP 01246000, Brazil
SP, 12245-750, Brazil
Nangjing, Jiangsu 210002, China
Ostrava - Poruba, 70852, Czechia
Kurashiki-shi, Okayama-ken 7010192, Japan
Kurashiki-shi, Okayama-ken 710-8602, Japan
Hirakata-shi, Osaka 5731191, Japan
Sunto-gun, Shizuoka 4118777, Japan
Chuo-ku, Tokyo 104-0045, Japan
Ube-shi, Yamaguchi 7550241, Japan
Akashi, Hyogo, 673-8558, Japan
Fukoka, 811-1395, Japan
Oskaka, 5340021, Japan
Sendai, Miyagi, 980-0873, Japan
Cercado, Peru
Karkow, 31-202, Poland
Hwasun-eup, Hwasun-gun, Jeollanam-do 519-763, South Korea
Benidorm-alicante, 03501, Spain
Taoyuan County, 33305, Taiwan